RU2012152633A - METHOD FOR OBTAINING BIMOSYAMOSIS - Google Patents
METHOD FOR OBTAINING BIMOSYAMOSIS Download PDFInfo
- Publication number
- RU2012152633A RU2012152633A RU2012152633/04A RU2012152633A RU2012152633A RU 2012152633 A RU2012152633 A RU 2012152633A RU 2012152633/04 A RU2012152633/04 A RU 2012152633/04A RU 2012152633 A RU2012152633 A RU 2012152633A RU 2012152633 A RU2012152633 A RU 2012152633A
- Authority
- RU
- Russia
- Prior art keywords
- bis
- hexane
- carboethoxymethylphenyl
- mannopyranosyloxy
- phenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 16
- RYWCQJDEHXJHRI-XJMXIVSISA-N 2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC(C(=C1)C=2C=C(CC(O)=O)C=CC=2)=CC=C1CCCCCCC(C=C1C=2C=C(CC(O)=O)C=CC=2)=CC=C1O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RYWCQJDEHXJHRI-XJMXIVSISA-N 0.000 claims abstract 37
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract 28
- -1 ethyl (2'-methoxybiphenyl-3-yl) acetic acid Chemical compound 0.000 claims abstract 17
- 229950007225 bimosiamose Drugs 0.000 claims abstract 14
- AGFBLMOECRWVDT-UHFFFAOYSA-N 2-[3-(2-methoxyphenyl)phenyl]acetic acid Chemical compound COC1=CC=CC=C1C1=CC=CC(CC(O)=O)=C1 AGFBLMOECRWVDT-UHFFFAOYSA-N 0.000 claims abstract 11
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 10
- PDHXVYUQWHNFRV-UHFFFAOYSA-N ethyl 2-[3-[5-[6-[3-[3-(2-ethoxy-2-oxoethyl)phenyl]-4-hydroxyphenyl]hexyl]-2-hydroxyphenyl]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(C=2C(=CC=C(CCCCCCC=3C=C(C(O)=CC=3)C=3C=C(CC(=O)OCC)C=CC=3)C=2)O)=C1 PDHXVYUQWHNFRV-UHFFFAOYSA-N 0.000 claims abstract 9
- RGLYBOVAJQTZBO-UHFFFAOYSA-N ethyl 2-[3-[5-[6-[3-[3-(2-ethoxy-2-oxoethyl)phenyl]-4-methoxyphenyl]hexyl]-2-methoxyphenyl]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(C=2C(=CC=C(CCCCCCC=3C=C(C(OC)=CC=3)C=3C=C(CC(=O)OCC)C=CC=3)C=2)OC)=C1 RGLYBOVAJQTZBO-UHFFFAOYSA-N 0.000 claims abstract 9
- WYLVUWWIGIGCBK-UHFFFAOYSA-N ethyl 2-[3-[5-[6-[3-[3-(2-ethoxy-2-oxoethyl)phenyl]-4-methoxyphenyl]-6-oxohexanoyl]-2-methoxyphenyl]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(C=2C(=CC=C(C=2)C(=O)CCCCC(=O)C=2C=C(C(OC)=CC=2)C=2C=C(CC(=O)OCC)C=CC=2)OC)=C1 WYLVUWWIGIGCBK-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000002904 solvent Substances 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 7
- PWAXUOGZOSVGBO-UHFFFAOYSA-N adipoyl chloride Chemical compound ClC(=O)CCCCC(Cl)=O PWAXUOGZOSVGBO-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000003960 organic solvent Substances 0.000 claims abstract 5
- 230000002378 acidificating effect Effects 0.000 claims abstract 4
- 238000002955 isolation Methods 0.000 claims abstract 4
- 125000004494 ethyl ester group Chemical group 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 4
- 239000000047 product Substances 0.000 claims 4
- 206010001889 Alveolitis Diseases 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000002841 Lewis acid Substances 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 150000007517 lewis acids Chemical class 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 claims 1
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- BBRRGKQZSUJDJR-UHFFFAOYSA-N C=1C=C(O)C(C=2C=C(CC(=O)OCC)C=CC=2)=CC=1C(CCCCC)C(C=1)=CC=C(O)C=1C1=CC=CC(CC(=O)OCC)=C1 Chemical compound C=1C=C(O)C(C=2C=C(CC(=O)OCC)C=CC=2)=CC=1C(CCCCC)C(C=1)=CC=C(O)C=1C1=CC=CC(CC(=O)OCC)=C1 BBRRGKQZSUJDJR-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 210000000683 abdominal cavity Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000007859 condensation product Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000025245 disorder of lacrimal gland Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 239000012265 solid product Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- LDERXAIJKAWVIH-UHFFFAOYSA-N ethyl 2-[3-(2-methoxyphenyl)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(C=2C(=CC=CC=2)OC)=C1 LDERXAIJKAWVIH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
1. Способ получения 1,6-бис-[3-(3-карбоксиметилфенил)-4-(2-α-D-маннопиранозилокси)фенил]гексана, соединения формулы (I)который содержит стадии превращения соединения (2'-метоксибифенил-3-ил)уксусной кислоты (А) в этиловый эфир (2'-метоксибифенил-3-ил)уксусной кислоты, который подвергают реакции с адипоилхлоридом, получая при этом 1,4-бис-[3-(3-карбоэтоксиметилфенил)-4-метоксибензоил]бутан (В), который затем каталитическим восстановлением превращают в 1,6-бис-[3-(3-карбоэтоксиметилфенил)-4-метоксифенил]гексан (С), который подвергают реакции с трибромидом бора в растворителе с получением 1,6-бис-[3-(3-карбоэтоксиметилфенил)-4-гидроксифенил]гексана (D), который подвергают реакции с защищенным маннопиранозилпроизводным, получая при этом производное 1,6-бис-[3-(3-карбоэтоксиметилфенил)-4-(тетра-О-защищенный-α-D-маннопиранозилокси)фенил]гексана, которое затем подвергают реакции в основных условиях, получая при этом 1,6-бис-[3-(3-карбоксиметилфенил)-4-(2-α-D-маннопиранозилокси)фенил]гексан, который необязательно перекристаллизовывают из одного, двух или нескольких органических растворителей и/или воды, получая при этом продукт, бимосиамозу формулы (I).2. Способ получения 1,6-бис-[3-(3-карбоксиметилфенил)-4-(2-α-D-маннопиранозилокси)фенил]гексана (I) по п.1, содержащий следующие стадии способа:а) (2'-метоксибифенил-3-ил)уксусную кислоту (А) превращают в кислотных условиях в этиловый эфир (2'-метоксибифенил-3-ил)уксусной кислоты, который затем подвергают реакции с адипоилхлоридом в растворителе, получая при этом 1,4-бис-[3-(3-карбоэтоксиметилфенил)-4-метоксибензоил]бутан (В), без выделения промежуточного продукта, этилового эфира (2'-метоксибифенил-3-ил)уксусной кислоты,1. A method for producing 1,6-bis- [3- (3-carboxymethylphenyl) -4- (2-α-D-mannopyranosyloxy) phenyl] hexane, a compound of formula (I) which contains the steps of converting the compound (2'-methoxybiphenyl- 3-yl) acetic acid (A) in (2'-methoxybiphenyl-3-yl) acetic acid ethyl ester, which is reacted with adipoyl chloride to give 1,4-bis- [3- (3-carboethoxymethylphenyl) -4 -methoxybenzoyl] butane (B), which is then catalytically reduced to 1,6-bis- [3- (3-carboethoxymethylphenyl) -4-methoxyphenyl] hexane (C), which is reacted with boron tribromide in a solvent to obtain 1,6-bis- [3- (3-carboethoxymethylphenyl) -4-hydroxyphenyl] hexane (D), which is reacted with a protected mannopyranosyl derivative to obtain a 1,6-bis [3- (3 β-carboethoxymethylphenyl) -4- (tetra-O-protected-α-D-mannopyranosyloxy) phenyl] hexane, which is then reacted under basic conditions to give 1,6-bis- [3- (3-carboxymethylphenyl) -4 - (2-α-D-mannopyranosyloxy) phenyl] hexane, which is optionally recrystallized from one, two or more organic solvents and / or water to obtain and this product bimosiamose of formula (I) .2. The method for producing 1,6-bis- [3- (3-carboxymethylphenyl) -4- (2-α-D-mannopyranosyloxy) phenyl] hexane (I) according to claim 1, containing the following process steps: a) (2'- methoxybiphenyl-3-yl) acetic acid (A) is converted under acidic conditions into ethyl (2'-methoxybiphenyl-3-yl) acetic acid, which is then reacted with adipoyl chloride in a solvent to obtain 1,4-bis- [ 3- (3-carboethoxymethylphenyl) -4-methoxybenzoyl] butane (B), without isolation of the intermediate, ethyl ester of (2'-methoxybiphenyl-3-yl) acetic acid,
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10162276 | 2010-05-07 | ||
EP10162276.9 | 2010-05-07 | ||
PCT/EP2011/057130 WO2011138365A1 (en) | 2010-05-07 | 2011-05-04 | Process for the preparation of bimosiamose |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012152633A true RU2012152633A (en) | 2014-06-20 |
Family
ID=44276097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012152633/04A RU2012152633A (en) | 2010-05-07 | 2011-05-04 | METHOD FOR OBTAINING BIMOSYAMOSIS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2566580A1 (en) |
JP (1) | JP2013525467A (en) |
KR (1) | KR20130056238A (en) |
CN (1) | CN103002951A (en) |
AU (1) | AU2011249843A1 (en) |
CA (1) | CA2798383A1 (en) |
RU (1) | RU2012152633A (en) |
WO (1) | WO2011138365A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5444050A (en) * | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
BR9608873A (en) * | 1995-06-29 | 1999-07-06 | Texas Biotechnology Corp | Small molecule di and trivalent selectin inhibitors |
US5712387A (en) * | 1996-05-20 | 1998-01-27 | Texas Biotechnology Corporation | High yield stereospecific mannosylation |
US5919768A (en) | 1996-06-26 | 1999-07-06 | Texas Biotechnology Corporation | Di- and trivalent small molecule selectin inhibitors |
EP1897533A1 (en) * | 2006-09-08 | 2008-03-12 | Revotar Biopharmaceuticals AG | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions |
EP1903049A1 (en) * | 2006-09-08 | 2008-03-26 | Revotar Biopharmaceuticals AG | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane |
EP1958637A1 (en) * | 2007-02-14 | 2008-08-20 | Revotar Biopharmaceuticals AG | Pharmaceutical composition for the treatment of IL-8 mediated diseases |
-
2011
- 2011-05-04 KR KR1020127029201A patent/KR20130056238A/en not_active Application Discontinuation
- 2011-05-04 WO PCT/EP2011/057130 patent/WO2011138365A1/en active Application Filing
- 2011-05-04 JP JP2013508490A patent/JP2013525467A/en not_active Withdrawn
- 2011-05-04 RU RU2012152633/04A patent/RU2012152633A/en not_active Application Discontinuation
- 2011-05-04 EP EP11720069A patent/EP2566580A1/en not_active Withdrawn
- 2011-05-04 CN CN2011800230987A patent/CN103002951A/en active Pending
- 2011-05-04 CA CA2798383A patent/CA2798383A1/en not_active Abandoned
- 2011-05-04 AU AU2011249843A patent/AU2011249843A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20130056238A (en) | 2013-05-29 |
JP2013525467A (en) | 2013-06-20 |
CN103002951A (en) | 2013-03-27 |
CA2798383A1 (en) | 2011-11-10 |
AU2011249843A1 (en) | 2012-11-29 |
WO2011138365A1 (en) | 2011-11-10 |
EP2566580A1 (en) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011281421A1 (en) | Process for preparing aminobenzoylbenzofuran derivatives | |
US9499507B2 (en) | Method for preparing 5-amino-benzoyl-benzofuran derivatives | |
JP5006311B2 (en) | Substituted tetrafluorobenzylaniline compound and method for producing pharmaceutically acceptable salt thereof | |
JPWO2015129654A1 (en) | Process for producing 1,1-disubstituted hydrazine compounds | |
WO2018207113A1 (en) | A process for the preparation of sglt2 inhibitor and intermediates thereof | |
FR2928148A1 (en) | COMBRETASTATINE PREPARATION PROCESS | |
RU2012152633A (en) | METHOD FOR OBTAINING BIMOSYAMOSIS | |
EA015790B1 (en) | A method of manufacturing 4'-[[4-methyl-6-(1-methyl-1h-benzimidazol-2-yl)-2-propyl-1h-benzimidazol-1yl]methyl]biphenyl-2-carboxylic acid (telmisartan) | |
WO2020182227A1 (en) | Preparation method for high purity liraglutide side chain | |
RU2673540C2 (en) | Process for preparation of levothyroxine and salts thereof | |
AU2008358758A1 (en) | A process for preparing atovaquone and associate intermediates | |
SU273822A1 (en) | Method of obtaining 2,4-dioxo-3-aryl-5-dichlormethylenoxazolydine | |
FODOR et al. | Configuration of diastereoisomeric 3-methoxy-4-hydroxyphenylpropanolamines | |
US20160214927A1 (en) | Process for the preparation of nepafenac | |
MXPA00011933A (en) | Phosphine reduction of azides to amines. | |
JP5144656B2 (en) | Gabapentin preparation process | |
JP7174851B2 (en) | Method for preparing (1R,3S)-3-amino-1-cyclopentanol and salts thereof | |
RU2768144C1 (en) | Method of producing 5-hydroxy-1,3,6-trimethyluracil | |
SU289092A1 (en) | METHOD OF OBTAINING CARBOBUNCTIONAL DERIVATIVES OF SILACYCLOGEXANE | |
JPH06199747A (en) | Production of l-alaninol | |
KR101849274B1 (en) | Method for producing 2-amino-6-methylnicotinic acid | |
RU2663899C1 (en) | Process for the preparation of 1-carbamoylmethyl-4-phenyl-2-pyrrolidone | |
JP2942342B2 (en) | Method for producing 1,6-di (Np-chlorophenylbiguanide) hexane | |
RU2605602C1 (en) | Method of producing sodium salt of (2,6-dichlorophenyl)amide carbopentoxysulphanilic acid | |
RU2141472C1 (en) | 5-nitro-4-oxopentanoic (5-nitrolevulinic) acid alkyl esters and method of their synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140505 |